Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Pulse Biosciences, Inc PLSE

Healthcare — Medical Instruments & Supplies
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
13.50
Total sells
3.02
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — 2 — — 2 —
Sell 1 — — — 3 — — — — — — —
Insider Ownership
70.16%

Capital & Financial Ratios

Market Cap
3,610.00
Revenue
1.19
Net Income
(80.06)
Free Cash Flow
(61.39)
Net Debt
(101.62)
Current Ratio
9.63
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
3,145.83
P/B ratio
37.47
Past 5Y EPS Growth
16.53%
This Y EPS Growth
(58.34%)
Next Y EPS Growth
(5.48%)
Next 5Y EPS Growth
(9.89%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 44.37 118.04 80.74 101.62
Receivables — — 0.27 0.12
Inventory — — 0.14 0.24
Other — — — —
45.33 119.45 83.42 105.70
2023 2024 2025 Q'26
Payables 1.84 1.67 2.78 2.83
ST’ Debt — — — —
Other — — — —
6.71 10.06 7.92 10.98
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 0.40 0.43 — —
—
’25 — — 0.09 0.26
0.35
’22 0.44 0.27 — (0.01)
0.70
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (14.59) (18.71) — —
—
’25 (13.52) (12.81) (13.04) (14.75)
(54.12)
’24 (9.78) (8.39) (9.02) (9.14)
(36.34)
’23 (6.57) (9.20) (10.49) (6.78)
(33.04)
’22 (15.59) (12.82) (10.63) (7.96)
(47.01)
’21 (11.69) (16.37) (13.35) (12.69)
(54.10)
’20 (9.62) (7.94) (8.55) (9.25)
(35.36)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (14.63) (18.80) — —
—
’25 (13.57) (12.93) (13.10) (14.86)
(54.46)
’24 (9.78) (8.42) (9.06) (9.20)
(36.47)
’23 (6.61) (9.22) (10.51) (6.82)
(33.16)
’22 (15.87) (12.84) (10.69) (8.01)
(47.41)
’21 (11.74) (16.46) (13.51) (12.83)
(54.53)
’20 (9.79) (7.87) (8.61) (9.53)
(35.81)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.27) (0.36) — —
—
’25 (0.25) (0.28) (0.29) (0.26)
(1.08)
’24 (0.18) — (0.21) (0.31)
(0.92)
’23 (0.26) (0.22) (0.19) (0.22)
(0.88)
’22 (0.58) (0.44) (0.49) (0.25)
(1.72)
’21 (0.71) (0.58) (0.48) (0.52)
(2.28)
’20 (0.57) (0.53) (0.51) (0.54)
(2.14)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 1.18 2.36 6.60 12.56 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 15.38 13.62 22.69 25.00 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 61 56 75 116 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.01 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — ‡‡‡‡‡ 0.70 — — 0.35 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (1,606.29%) — — (54.00%) — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.50) (42.21) (53.58) (72.78) — — —
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (8,357.86%) 0.00% 0.00% (20,794.57%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.50) (42.21) (53.58) (72.78) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.36 1.21 1.18 1.07 — — —
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.02 0.00 0.00 0.01 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.72) (0.88) (0.92) (1.08) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.39) (0.66) (0.62) (0.80) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.40) (0.67) (0.62) (0.81) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.07) 0.89 1.97 1.20 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.94 49.74 58.40 67.40 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — ‡‡‡ 0.00 — — 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — ‡‡‡ 60.44 — — 1,526.95 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — ‡‡‡‡‡ 0.00 — — 11.47 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — ‡‡‡ 63.54 — — 1,409.21 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
— — — — — ‡‡‡‡‡ (2.07) — — (15.69) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.01) (33.04) (36.34) (54.12) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.40) (0.12) (0.12) (0.33) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.41) (33.16) (36.47) (54.46) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.17 38.62 109.39 75.50 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 65.92 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.78 (44.36) (118.04) (80.73) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.25) 44.36 114.86 80.66 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (88.56%) (61.61%) (55.93%) (64.12%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,434.21%) 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (349.89%) (200.47%) (67.31%) (74.45%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Pulse Biosciences (PLSE) has embodied biotech volatility, surging over 1,000% from 2016 lows to 2021 peaks before plunging 97% in 2022, driven more by hype around its NanoPulse Stimulation (NPS) technology than substantive revenue, which remains negligible at under $1 million recently. Trading near recent highs with analyst targets implying 13% mean upside (up to 30% potential), it tempts speculators amid CellFX system pilots in dermatology and cardiac applications—but fundamentals flash warning signs of endless cash burn, explosive dilution (shares up 430%), and deteriorating EPS from -0.86 to projected -1.20 through 2027.

Persistent losses totaling $50-100 million annually, negative gross margins, and ROE/ROA in the red underscore a profitability black hole, fueled by R&D and headcount swings while revenue per employee lags peers dramatically. Insider activity leans bearish, with $4.2 million in sells dwarfing a single $2.8 million buy, signaling profit-taking post-rally rather than conviction. Balance sheet strains from $36 million yearly free cash flow burns threaten the $109 million working capital buffer, echoing past hype cycles that decoupled from operational reality.

Analysts project revenue exploding to $11 million by 2027, but with losses widening first and sky-high EV/Sales multiples, it’s priced for flawless execution in a skeptical M&A environment. This contrarian analysis probes whether PLSE is a disruptive phoenix or another dilution trap—read the full breakdown for the risks, catalysts, and prudent verdict.

Read full commentary →

Pulse Biosciences, Inc (PLSE) Latest News

News by impact score

Fine-tune

15 Sep

3 , 7:00 AM
Pulse Biosciences completes enrollment in the PRECISE-BTN clinical study evaluating the nPulse Vybrance percutaneous electrode system for symptomatic benign thyroid nodules. Enrollment completion advances device validation in a key indication but remains a mid-stage milestone without immediate revenue or regulatory effects.

16 Aug

4 www.marketbeat.com, 9:01 AM
Pulse Biosciences advances nanosecond pulsed field ablation platform targeting atrial fibrillation treatment. Nanosecond PFA platform targets major AFib market with potential to transform treatment options and company trajectory.

3 , 2:10 AM
Pulse Biosciences prices a $75 million offering while questioning if the stock is fully valued. A $75 million offering creates share dilution that can affect near-term stock performance and investor sentiment.

13 Aug

4 transcript www.fool.com, 7:31 PM
Pulse Biosciences, Inc. (PLSE) held its Q2 2026 earnings call to review financial results, operations and outlook. Q2 2026 earnings call delivers financial results and forward guidance that can materially shift PLSE valuation and investor views.

7 Aug

4 transcript , 1:08 AM
Pulse Biosciences Inc highlighted accelerated enrollment in its Q2 2026 earnings call. Accelerated enrollment signals faster clinical progress with potential to boost revenue trajectory.

3 transcript app.moby.co, 8:30 AM
Pulse Biosciences reported Q2 2026 financial results and operational updates during its earnings call. Quarterly earnings calls disclose financial metrics and guidance that moderately shape near-term investor views and stock movement.

3 transcript www.marketbeat.com, 4:03 AM
Pulse Biosciences Q2 earnings call covered financial results, operational updates and outlook for the company. Q2 earnings call delivers financial metrics and guidance that moderately influence investor sentiment and near-term stock performance.

6 Aug

3 , 7:10 PM
Pulse Biosciences, Inc (PLSE) reported a Q2 loss and missed revenue estimates. Q2 loss and missed revenue estimates indicate financial underperformance likely affecting near-term market sentiment for Pulse Biosciences.

3 , 4:05 PM
Pulse Biosciences issued business updates and second quarter 2026 financial results. Quarterly financial results typically provide moderate influence on valuation and market perception.

29 Jul

3 , 7:00 AM
Pulse Biosciences surpasses enrollment midpoint in NANOPULSE-AF IDE Pivotal Study. Milestone in pivotal trial supports regulatory path for core technology but stops short of approval or launch.

24 Jul

3 www.barchart.com, 10:30 AM
Pulse Biosciences (PLSE) stock reaches a new five-year high. Five-year high lifts short-term sentiment without altering core operations.

9 Jun

3 Simply Wall St., 7:08 AM
New analyst coverage and insider buying may have shifted Pulse Biosciences' (PLSE) investment narrative. Analyst coverage combined with insider purchases moderately lifts PLSE market sentiment and visibility.

12 May

4 Business Wire, 7:00 AM
Pulse Biosciences' co-chairmen purchased approximately $13.3 million in company equity through an at-the-market (ATM) offering. Co-chairmen's $13.3 million ATM equity buy signals strong insider confidence, likely driving positive investor sentiment and stock price momentum.

10 May

4 Simply Wall St., 12:08 PM
Pulse Biosciences (PLSE) is quietly redefining its core identity around atrial fibrillation, potentially pivoting from prior focuses amid developments in its Nano-Pulse Stimulation technology for cardiac treatments. Strategic redefinition around atrial fibrillation signals major shift in core operations and market positioning for PLSE.

8 May

4 transcript www.fool.com, 10:18 AM
Pulse Biosciences, Inc. (PLSE) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook significantly shaping PLSE's market trajectory.

4 transcript app.moby.co, 8:30 AM
Pulse Biosciences, Inc. held its Q1 2026 earnings call covering financial results and company outlook. Q1 earnings call delivers key financial metrics and guidance that can shift PLSE stock trajectory and sentiment.

3 www.marketbeat.com, 4:05 PM
Pulse Biosciences Q1 earnings call highlights financial results, operational progress, and strategic updates. Q1 earnings call highlights moderately influence financial performance and investor sentiment without fundamental changes.

6 May

4 Business Wire, 8:00 AM
Turbett Surgical appoints Kevin Danahy as President and Chief Executive Officer to lead its growth phase. Leadership change at Turbett Surgical with experienced CEO targets growth, significantly enhancing Pulse Biosciences' strategic positioning and investor sentiment.

4 May

4 transcript www.fool.com, 4:32 PM
Pulse Biosciences, Inc. (PLSE) released Q4 2025 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q4 earnings transcripts disclose critical financial metrics, strategic initiatives, and outlook that significantly influence investor sentiment and stock trajectory.

4 Business Wire, 7:00 AM
Pulse Biosciences, Inc. (PLSE) announced business updates and first quarter 2026 financial results. Quarterly financial results combined with business updates represent major strategic and operational developments likely to alter investor sentiment and company trajectory.

25 Apr

4 Business Wire, 1:00 PM
Pulse Biosciences presented positive outcomes in late-breaking updated data from its nPulse Cardiac Catheter System at Heart Rhythm 2026. Positive late-breaking data from nPulse Cardiac Catheter System at major cardiology conference indicates significant clinical progress likely to improve PLSE's competitive position and investor sentiment.

23 Apr

4 Simply Wall St., 4:06 AM
Pulse Biosciences' clinical trials and conference presentations spotlight advancements in Pulse Field Ablation technology, positively reframing the company's narrative and potential. Trials and conference spotlight signal major progress in Pulse Field Ablation, poised to significantly boost PLSE's competitive position and investor sentiment.

20 Apr

4 , 10:49 AM
Pulse Biosciences (PLSE) has enrolled its first patients in a pivotal clinical trial evaluating its Nano-Pulse Stimulation technology for treating drug-refractory symptomatic paroxysmal atrial fibrillation, marking a key milestone toward potential FDA approval. First-patient enrollment in a pivotal atrial fibrillation trial represents significant progress toward regulatory approval and commercialization of a novel treatment in a large market.

13 Apr

4 Zacks, 9:50 AM
Pulse Biosciences initiates patient enrollment in the NANOPULSE-AF study evaluating its NanoPulse Technology for non-thermal cardiac ablation in atrial fibrillation patients. Initiating patient enrollment advances a key clinical trial milestone that could significantly boost Pulse Biosciences' pipeline progress and investor sentiment.

12 Apr

4 Simply Wall St., 4:06 PM
Pulse Biosciences launches new atrial fibrillation study and appoints key C-suite executives to potentially reframe its pulsed field ablation strategy. New AF study and C-suite hires signal major strategic advancements in PLSE's core PFA technology, likely enhancing clinical momentum and investor confidence.

10 Apr

3 www.medtechdive.com, 12:12 AM
Pulse Biosciences, Inc. (PLSE) hired Liane Teplitsky as Chief Operating Officer. Hiring a new COO strengthens operational leadership and supports strategic execution in key areas.

7 Apr

4 Business Wire, 7:00 AM
Pulse Biosciences enrolls first patients in NANOPULSE-AF IDE pivotal clinical study evaluating nPulse™ Cardiac Catheter System for atrial fibrillation treatment. First-patient enrollment in pivotal IDE study marks critical progress toward FDA approval and commercialization of nPulse system.

26 Mar

4 Zacks, 12:03 PM
Pulse Biosciences, Inc. (PLSE) accelerates its cardiac catheter program after breakthrough atrial fibrillation (AFib) data. Breakthrough AFib data drives acceleration of PLSE's cardiac catheter program, signaling major pipeline advancement with significant potential to enhance competitive positioning and market performance.

21 Mar

4 www.marketbeat.com, 1:05 PM
Pulse Biosciences announces 96% 12-month rhythm control in atrial fibrillation study and targets Q2 start for U.S. AF IDE study. 96% rhythm control data and Q2 IDE study initiation mark significant clinical and regulatory progress boosting commercialization prospects.

17 Mar

4 Business Wire, 7:00 AM
Pulse Biosciences announces strategic alignment to accelerate its cardiac catheter program after exceptional long-term atrial fibrillation (AFib) clinical data. Strategic acceleration of cardiac catheter program driven by exceptional long-term AFib data represents a major advancement in a key medtech area with strong potential to enhance market position and performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us